HB 3454

Select Language
  ×
The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.
Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.
The English language version is always the official and authoritative version of this website.
NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.
  Choose Language
  English
  Afrikaans
  Albanian
  Arabic
  Armenian
  Azerbaijani
  Basque
  Bengali
  Bosnian
  Catalan
  Croatian
  Czech
  Danish
  Dutch
  Esperanto
  Estonian
  Filipino
  Finnish
  French
  Galician
  Georgian
  German
  Greek
  Gujarati
  Haitian Creole
  Hausa
  Hawaiian
  Hebrew
  Hindi
  Hungarian
  Icelandic
  Indonesian
  Interlingua
  Interlingue
  Inuktitut
  Irish
  Italian
  Japanese
  Javanese
  Kannada
  Khmer
  Korean
  Latin
  Latvian
  Lithuanian
  Luxembourgish
  Macedonian
  Malagasy
  Malayalam
  Maltese
  Maori
  Marathi
  Myanmar
  Nepali
  Norwegian
  Odia
  Pashto
  Punjabi
  Romanian
  Russian
  Samoan
  Sango
  Sanskrit
  Sardinian
  Sindhi
  Sinhala
  Slovak
  Slovenian
  Somali
  Southern Sotho
  Spanish
  Sundanese
  Swahili
  Swedish
  Tamil
  Telugu
  Thai
  Tigrinya
  Tonga
  Turkish
  Ukrainian
  Urdu
  Vietnamese
  Welsh
  Xhosa
  Yiddish
  Yoruba
  Zulu
  Powered by Translate
  Close
Illinois General Assembly
Top Navigation Bar
  Translate
  Learn
  Select General Assembly
  Search the 104th General Assembly
  Enter search terms for legislation, members, committees, or schedules.
  ILGA.GOV
Mobile Top Bar
  Search the 104th General Assembly
  Enter keywords to search the Illinois General Assembly website.
Full Text of HB3454
Home
Legislation
Full Text
	HB3454 - 104th General Assembly
		Bill Status
		Full Text
		Votes
		Witness Slips
	Select Menu
	Bill Status
	Full Text
	Votes
	Witness Slips
	Printer Friendly Version
			Introduced
			Engrossed
			Enrolled
			Senate Amendment 001
			Senate Amendment 002
			Public Act
		Printer Friendly Version
		Introduced
		Engrossed
		Enrolled
		Senate Amendment 001
		Senate Amendment 002
		Public Act
			 Open PDF
		HB3454 Enrolled		LRB104 09749 BDA 19815 b
1    AN ACT concerning health.
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4    Section 5. The Illinois State Police Act is amended by
5changing Section 40 as follows:
6    (20 ILCS 2610/40)
7    Sec. 40. Administration of epinephrine.
8    (a) This Section, along with Section 10.19 of the Illinois
9Police Training Act, may be referred to as the Annie LeGere
10Law.
11    (b) For the purposes of this Section, "epinephrine 
12delivery system" ["epinephrine auto-injector"] means a
13single-use device used for the automatic injection of a
14pre-measured dose of epinephrine into the human body
15prescribed in the name of the Illinois State Police.
16    (c) The Illinois State Police may conduct or approve a
17training program for State Police officers to recognize and
18respond to anaphylaxis, including, but not limited to:
19        (1) how to recognize symptoms of an allergic reaction;
20        (2) how to respond to an emergency involving an
21    allergic reaction;
22        (3) how to administer an epinephrine delivery system
23    [epinephrine auto-injector];
		HB3454 Enrolled	- 2 -	LRB104 09749 BDA 19815 b
1        (4) how to respond to an individual with a known
2    allergy as well as an individual with a previously unknown
3    allergy;
4        (5) a test demonstrating competency of the knowledge
5    required to recognize anaphylaxis and administer an
6    epinephrine delivery system [epinephrine auto-injector]; and
7        (6) other criteria as determined in rules adopted by
8    the Illinois State Police.
9    (d) The Illinois State Police may authorize a State Police
10officer who has completed the training program under
11subsection (c) to carry, administer, or assist with the
12administration of epinephrine delivery systems [epinephrine ]
13[auto-injectors] whenever he or she is performing official
14duties.
15    (e) The Illinois State Police must establish a written
16policy to control the acquisition, storage, transportation,
17administration, and disposal of epinephrine delivery systems
18[epinephrine auto-injectors] before it allows any State Police
19officer to carry and administer epinephrine delivery systems
20[epinephrine auto-injectors].
21    (f) A physician, physician assistant with prescriptive
22authority, or advanced practice registered nurse with
23prescriptive authority may provide a standing protocol or
24prescription for epinephrine delivery systems [epinephrine ]
25[auto-injectors] in the name of the Illinois State Police to be
26maintained for use when necessary.
		HB3454 Enrolled	- 3 -	LRB104 09749 BDA 19815 b
1    (g) When a State Police officer administers an epinephrine 
2delivery system [epinephrine auto-injector] in good faith, the
3officer and the Illinois State Police, and its employees and
4agents, including a physician, physician assistant with
5prescriptive authority, or advanced practice registered nurse
6with prescriptive authority who provides a standing order or
7prescription for an epinephrine delivery system [epinephrine ]
8[auto-injector], incur no civil or professional liability,
9except for willful and wanton conduct, as a result of any
10injury or death arising from the use of an epinephrine 
11delivery system [epinephrine auto-injector].
12(Source: P.A. 104-24, eff. 1-1-26.)
13    Section 10. The Illinois Police Training Act is amended by
14changing Section 10.19 as follows:
15    (50 ILCS 705/10.19)
16    Sec. 10.19. Training; administration of epinephrine.
17    (a) This Section, along with Section 40 of the Illinois
18State Police Act, may be referred to as the Annie LeGere Law.
19    (b) For purposes of this Section, "epinephrine delivery 
20system" ["epinephrine auto-injector"] means a single-use device
21used for the automatic injection of a pre-measured dose of
22epinephrine into the human body prescribed in the name of a
23local law enforcement agency.
24    (c) The Board shall conduct or approve an optional
		HB3454 Enrolled	- 4 -	LRB104 09749 BDA 19815 b
1advanced training program for law enforcement officers to
2recognize and respond to anaphylaxis, including the
3administration of an epinephrine delivery system [epinephrine ]
4[auto-injector]. The training must include, but is not limited
5to:
6        (1) how to recognize symptoms of an allergic reaction;
7        (2) how to respond to an emergency involving an
8    allergic reaction;
9        (3) how to administer an epinephrine delivery system
10    [epinephrine auto-injector];
11        (4) how to respond to an individual with a known
12    allergy as well as an individual with a previously unknown
13    allergy;
14        (5) a test demonstrating competency of the knowledge
15    required to recognize anaphylaxis and administer an
16    epinephrine delivery system [epinephrine auto-injector]; and
17        (6) other criteria as determined in rules adopted by
18    the Board.
19    (d) A local law enforcement agency may authorize a law
20enforcement officer who has completed an optional advanced
21training program under subsection (c) to carry, administer, or
22assist with the administration of epinephrine delivery systems
23[epinephrine auto-injectors] provided by the local law
24enforcement agency whenever the officer is performing official
25duties.
26    (e) A local law enforcement agency that authorizes its
		HB3454 Enrolled	- 5 -	LRB104 09749 BDA 19815 b
1officers to carry and administer epinephrine delivery systems
2[epinephrine auto-injectors] under subsection (d) must establish
3a policy to control the acquisition, storage, transportation,
4administration, and disposal of epinephrine delivery systems
5[epinephrine auto-injectors] and to provide continued training
6in the administration of epinephrine delivery systems
7[epinephrine auto-injectors].
8    (f) A physician, physician assistant with prescriptive
9authority, or advanced practice registered nurse with
10prescriptive authority may provide a standing protocol or
11prescription for epinephrine delivery systems [epinephrine ]
12[auto-injectors] in the name of a local law enforcement agency
13to be maintained for use when necessary.
14    (g) When a law enforcement officer administers an
15epinephrine delivery system [epinephrine auto-injector] in good
16faith, the law enforcement officer and local law enforcement
17agency, and its employees and agents, including a physician,
18physician assistant with prescriptive authority, or advanced
19practice registered nurse with prescriptive authority who
20provides a standing order or prescription for an epinephrine 
21delivery system [epinephrine auto-injector], incur no civil or
22professional liability, except for willful and wanton conduct,
23or as a result of any injury or death arising from the use of
24an epinephrine delivery system [epinephrine auto-injector].
25(Source: P.A. 102-538, eff. 8-20-21; 102-694, eff. 1-7-22;
26103-154, eff. 6-30-23.)
		HB3454 Enrolled	- 6 -	LRB104 09749 BDA 19815 b
1    Section 15. The School Code is amended by changing Section
222-30 as follows:
3    (105 ILCS 5/22-30)
4    Sec. 22-30. Self-administration and self-carry of asthma
5medication and epinephrine delivery systems [injectors];
6administration of undesignated epinephrine delivery systems
7[injectors]; administration of an opioid antagonist;
8administration of undesignated asthma medication; supply of
9undesignated oxygen tanks; asthma episode emergency response
10protocol.
11    (a) For the purpose of this Section only, the following
12terms shall have the meanings set forth below:
13    "Asthma action plan" means a written plan developed with a
14pupil's medical provider to help control the pupil's asthma.
15The goal of an asthma action plan is to reduce or prevent
16flare-ups and emergency department visits through day-to-day
17management and to serve as a student-specific document to be
18referenced in the event of an asthma episode.
19    "Asthma episode emergency response protocol" means a
20procedure to provide assistance to a pupil experiencing
21symptoms of wheezing, coughing, shortness of breath, chest
22tightness, or breathing difficulty.
23    "Epinephrine delivery system" means any form of 
24epinephrine that is approved by the United States Food and 
		HB3454 Enrolled	- 7 -	LRB104 09749 BDA 19815 b
1Drug Administration, including any device that contains a dose 
2of epinephrine, and that is used to administer epinephrine 
3into the human body to prevent or treat a life-threatening 
4allergic reaction [injector" includes an auto-injector approved ]
5[by the United States Food and Drug Administration for the ]
6[administration of epinephrine and a pre-filled syringe ]
7[approved by the United States Food and Drug Administration and ]
8[used for the administration of epinephrine that contains a ]
9[pre-measured dose of epinephrine that is equivalent to the ]
10[dosages used in an auto-injector].
11    "Asthma medication" means quick-relief asthma medication,
12including albuterol or other short-acting bronchodilators,
13that is approved by the United States Food and Drug
14Administration for the treatment of respiratory distress.
15"Asthma medication" includes medication delivered through a
16device, including a metered dose inhaler with a reusable or
17disposable spacer or a nebulizer with a mouthpiece or mask.
18    "Opioid antagonist" means a drug that binds to opioid
19receptors and blocks or inhibits the effect of opioids acting
20on those receptors, including, but not limited to, naloxone
21hydrochloride or any other similarly acting drug approved by
22the U.S. Food and Drug Administration.
23    "Respiratory distress" means the perceived or actual
24presence of wheezing, coughing, shortness of breath, chest
25tightness, breathing difficulty, or any other symptoms
26consistent with asthma. Respiratory distress may be
		HB3454 Enrolled	- 8 -	LRB104 09749 BDA 19815 b
1categorized as "mild-to-moderate" or "severe".
2    "School nurse" means a registered nurse working in a
3school with or without licensure endorsed in school nursing.
4    "Self-administration" means a pupil's discretionary use of
5his or her prescribed asthma medication or epinephrine
6delivery system [injector].
7    "Self-carry" means a pupil's ability to carry his or her
8prescribed asthma medication or epinephrine delivery system
9[injector].
10    "Standing protocol" may be issued by (i) a physician
11licensed to practice medicine in all its branches, (ii) a
12licensed physician assistant with prescriptive authority, or
13(iii) a licensed advanced practice registered nurse with
14prescriptive authority.
15    "Trained personnel" means any school employee or volunteer
16personnel authorized in Sections 10-22.34, 10-22.34a, and
1710-22.34b of this Code who has completed training under
18subsection (g) of this Section to recognize and respond to
19anaphylaxis, an opioid overdose, or respiratory distress.
20    "Undesignated asthma medication" means asthma medication
21prescribed in the name of a school district, public school,
22charter school, or nonpublic school.
23    "Undesignated epinephrine delivery system [injector]" means
24an epinephrine delivery system [injector] prescribed in the name
25of a school district, public school, charter school, or
26nonpublic school.
		HB3454 Enrolled	- 9 -	LRB104 09749 BDA 19815 b
1    (b) A school, whether public, charter, or nonpublic, must
2permit the self-administration and self-carry of asthma
3medication by a pupil with asthma or the self-administration
4and self-carry of an epinephrine delivery system [injector] by a
5pupil, provided that:
6        (1) the parents or guardians of the pupil provide to
7    the school (i) written authorization from the parents or
8    guardians for (A) the self-administration and self-carry
9    of asthma medication or (B) the self-carry of asthma
10    medication or (ii) for (A) the self-administration and
11    self-carry of an epinephrine delivery system [injector] or
12    (B) the self-carry of an epinephrine delivery system
13    [injector], written authorization from the pupil's
14    physician, physician assistant, or advanced practice
15    registered nurse; and
16        (2) the parents or guardians of the pupil provide to
17    the school (i) the prescription label, which must contain
18    the name of the asthma medication, the prescribed dosage,
19    and the time at which or circumstances under which the
20    asthma medication is to be administered, or (ii) for the
21    self-administration or self-carry of an epinephrine
22    delivery system [injector], a written statement from the
23    pupil's physician, physician assistant, or advanced
24    practice registered nurse containing the following
25    information:
26            (A) the name and purpose of the epinephrine
		HB3454 Enrolled	- 10 -	LRB104 09749 BDA 19815 b
1        delivery system [injector];
2            (B) the prescribed dosage; and
3            (C) the time or times at which or the special
4        circumstances under which the epinephrine delivery 
5        system [injector] is to be administered.
6The information provided shall be kept on file in the office of
7the school nurse or, in the absence of a school nurse, the
8school's administrator.
9    (b-5) A school district, public school, charter school, or
10nonpublic school may authorize the provision of a
11student-specific or undesignated epinephrine delivery system
12[injector] to a student or any personnel authorized under a
13student's Individual Health Care Action Plan, allergy
14emergency action plan, or plan pursuant to Section 504 of the
15federal Rehabilitation Act of 1973 to administer an
16epinephrine delivery system [injector] to the student, that
17meets the student's prescription on file.
18    (b-10) The school district, public school, charter school,
19or nonpublic school may authorize a school nurse or trained
20personnel to do the following: (i) provide an undesignated
21epinephrine delivery system [injector] to a student for
22self-administration only or any personnel authorized under a
23student's Individual Health Care Action Plan, allergy
24emergency action plan, plan pursuant to Section 504 of the
25federal Rehabilitation Act of 1973, or individualized
26education program plan to administer to the student that meets
		HB3454 Enrolled	- 11 -	LRB104 09749 BDA 19815 b
1the student's prescription on file; (ii) administer an
2undesignated epinephrine delivery system [injector] that meets
3the prescription on file to any student who has an Individual
4Health Care Action Plan, allergy emergency action plan, plan
5pursuant to Section 504 of the federal Rehabilitation Act of
61973, or individualized education program plan that authorizes
7the use of an epinephrine delivery system [injector]; (iii)
8administer an undesignated epinephrine delivery system
9[injector] to any person that the school nurse or trained
10personnel in good faith believes is having an anaphylactic
11reaction; (iv) administer an opioid antagonist to any person
12that the school nurse or trained personnel in good faith
13believes is having an opioid overdose; (v) provide
14undesignated asthma medication to a student for
15self-administration only or to any personnel authorized under
16a student's Individual Health Care Action Plan or asthma
17action plan, plan pursuant to Section 504 of the federal
18Rehabilitation Act of 1973, or individualized education
19program plan to administer to the student that meets the
20student's prescription on file; (vi) administer undesignated
21asthma medication that meets the prescription on file to any
22student who has an Individual Health Care Action Plan or
23asthma action plan, plan pursuant to Section 504 of the
24federal Rehabilitation Act of 1973, or individualized
25education program plan that authorizes the use of asthma
26medication; and (vii) administer undesignated asthma
		HB3454 Enrolled	- 12 -	LRB104 09749 BDA 19815 b
1medication to any person that the school nurse or trained
2personnel believes in good faith is having respiratory
3distress.
4    (c) The school district, public school, charter school, or
5nonpublic school must inform the parents or guardians of the
6pupil, in writing, that the school district, public school,
7charter school, or nonpublic school and its employees and
8agents, including a physician, physician assistant, or
9advanced practice registered nurse providing standing protocol
10and a prescription for school epinephrine delivery systems
11[injectors], an opioid antagonist, or undesignated asthma
12medication, are to incur no liability or professional
13discipline, except for willful and wanton conduct, as a result
14of any injury arising from the administration of asthma
15medication, an epinephrine delivery system [injector], or an
16opioid antagonist regardless of whether authorization was
17given by the pupil's parents or guardians or by the pupil's
18physician, physician assistant, or advanced practice
19registered nurse. The parents or guardians of the pupil must
20sign a statement acknowledging that the school district,
21public school, charter school, or nonpublic school and its
22employees and agents are to incur no liability, except for
23willful and wanton conduct, as a result of any injury arising
24from the administration of asthma medication, an epinephrine
25delivery system [injector], or an opioid antagonist regardless
26of whether authorization was given by the pupil's parents or
		HB3454 Enrolled	- 13 -	LRB104 09749 BDA 19815 b
1guardians or by the pupil's physician, physician assistant, or
2advanced practice registered nurse and that the parents or
3guardians must indemnify and hold harmless the school
4district, public school, charter school, or nonpublic school
5and its employees and agents against any claims, except a
6claim based on willful and wanton conduct, arising out of the
7administration of asthma medication, an epinephrine delivery 
8system [injector], or an opioid antagonist regardless of whether
9authorization was given by the pupil's parents or guardians or
10by the pupil's physician, physician assistant, or advanced
11practice registered nurse.
12    (c-5) When a school nurse or trained personnel administers
13an undesignated epinephrine delivery system [injector] to a
14person whom the school nurse or trained personnel in good
15faith believes is having an anaphylactic reaction, administers
16an opioid antagonist to a person whom the school nurse or
17trained personnel in good faith believes is having an opioid
18overdose, or administers undesignated asthma medication to a
19person whom the school nurse or trained personnel in good
20faith believes is having respiratory distress, notwithstanding
21the lack of notice to the parents or guardians of the pupil or
22the absence of the parents or guardians signed statement
23acknowledging no liability, except for willful and wanton
24conduct, the school district, public school, charter school,
25or nonpublic school and its employees and agents, and a
26physician, a physician assistant, or an advanced practice
		HB3454 Enrolled	- 14 -	LRB104 09749 BDA 19815 b
1registered nurse providing standing protocol and a
2prescription for undesignated epinephrine delivery systems
3[injectors], an opioid antagonist, or undesignated asthma
4medication, are to incur no liability or professional
5discipline, except for willful and wanton conduct, as a result
6of any injury arising from the use of an undesignated
7epinephrine delivery system [injector], the use of an opioid
8antagonist, or the use of undesignated asthma medication,
9regardless of whether authorization was given by the pupil's
10parents or guardians or by the pupil's physician, physician
11assistant, or advanced practice registered nurse.
12    (d) The permission for self-administration and self-carry
13of asthma medication or the self-administration and self-carry
14of an epinephrine delivery system [injector] is effective for
15the school year for which it is granted and shall be renewed
16each subsequent school year upon fulfillment of the
17requirements of this Section.
18    (e) Provided that the requirements of this Section are
19fulfilled, a pupil with asthma may self-administer and
20self-carry his or her asthma medication or a pupil may
21self-administer and self-carry an epinephrine delivery system
22[injector] (i) while in school, (ii) while at a school-sponsored
23activity, (iii) while under the supervision of school
24personnel, or (iv) before or after normal school activities,
25such as while in before-school or after-school care on
26school-operated property or while being transported on a
		HB3454 Enrolled	- 15 -	LRB104 09749 BDA 19815 b
1school bus.
2    (e-5) Provided that the requirements of this Section are
3fulfilled, a school nurse or trained personnel may administer
4an undesignated epinephrine delivery system [injector] to any
5person whom the school nurse or trained personnel in good
6faith believes to be having an anaphylactic reaction (i) while
7in school, (ii) while at a school-sponsored activity, (iii)
8while under the supervision of school personnel, or (iv)
9before or after normal school activities, such as while in
10before-school or after-school care on school-operated property
11or while being transported on a school bus. A school nurse or
12trained personnel may carry undesignated epinephrine delivery 
13systems [injectors] on his or her person while in school or at a
14school-sponsored activity.
15    (e-10) Provided that the requirements of this Section are
16fulfilled, a school nurse or trained personnel may administer
17an opioid antagonist to any person whom the school nurse or
18trained personnel in good faith believes to be having an
19opioid overdose (i) while in school, (ii) while at a
20school-sponsored activity, (iii) while under the supervision
21of school personnel, or (iv) before or after normal school
22activities, such as while in before-school or after-school
23care on school-operated property. A school nurse or trained
24personnel may carry an opioid antagonist on his or her person
25while in school or at a school-sponsored activity.
26    (e-15) If the requirements of this Section are met, a
		HB3454 Enrolled	- 16 -	LRB104 09749 BDA 19815 b
1school nurse or trained personnel may administer undesignated
2asthma medication to any person whom the school nurse or
3trained personnel in good faith believes to be experiencing
4respiratory distress (i) while in school, (ii) while at a
5school-sponsored activity, (iii) while under the supervision
6of school personnel, or (iv) before or after normal school
7activities, including before-school or after-school care on
8school-operated property. A school nurse or trained personnel
9may carry undesignated asthma medication on his or her person
10while in school or at a school-sponsored activity.
11    (f) The school district, public school, charter school, or
12nonpublic school may maintain a supply of undesignated
13epinephrine delivery systems [injectors] in any secure location
14that is accessible before, during, and after school where an
15allergic person is most at risk, including, but not limited
16to, classrooms and lunchrooms. A physician, a physician
17assistant who has prescriptive authority in accordance with
18Section 7.5 of the Physician Assistant Practice Act of 1987,
19or an advanced practice registered nurse who has prescriptive
20authority in accordance with Section 65-40 of the Nurse
21Practice Act may prescribe undesignated epinephrine delivery 
22systems [injectors] in the name of the school district, public
23school, charter school, or nonpublic school to be maintained
24for use when necessary. Any supply of epinephrine delivery 
25systems [injectors] shall be maintained in accordance with the
26manufacturer's instructions.
		HB3454 Enrolled	- 17 -	LRB104 09749 BDA 19815 b
1    The school district, public school, charter school, or
2nonpublic school shall maintain a supply of an opioid
3antagonist in any secure location where an individual may have
4an opioid overdose, unless there is a shortage of opioid
5antagonists, in which case the school district, public school,
6charter school, or nonpublic school shall make a reasonable
7effort to maintain a supply of an opioid antagonist. Unless
8the school district, public school, charter school, or
9nonpublic school is able to obtain opioid antagonists without
10a prescription, a health care professional who has been
11delegated prescriptive authority for opioid antagonists in
12accordance with Section 5-23 of the Substance Use Disorder Act
13shall prescribe opioid antagonists in the name of the school
14district, public school, charter school, or nonpublic school,
15to be maintained for use when necessary. Any supply of opioid
16antagonists shall be maintained in accordance with the
17manufacturer's instructions.
18    The school district, public school, charter school, or
19nonpublic school may maintain a supply of asthma medication in
20any secure location that is accessible before, during, or
21after school where a person is most at risk, including, but not
22limited to, a classroom or the nurse's office. A physician, a
23physician assistant who has prescriptive authority under
24Section 7.5 of the Physician Assistant Practice Act of 1987,
25or an advanced practice registered nurse who has prescriptive
26authority under Section 65-40 of the Nurse Practice Act may
		HB3454 Enrolled	- 18 -	LRB104 09749 BDA 19815 b
1prescribe undesignated asthma medication in the name of the
2school district, public school, charter school, or nonpublic
3school to be maintained for use when necessary. Any supply of
4undesignated asthma medication must be maintained in
5accordance with the manufacturer's instructions.
6    A school district that provides special educational
7facilities for children with disabilities under Section
814-4.01 of this Code may maintain a supply of undesignated
9oxygen tanks in any secure location that is accessible before,
10during, and after school where a person with developmental
11disabilities is most at risk, including, but not limited to,
12classrooms and lunchrooms. A physician, a physician assistant
13who has prescriptive authority in accordance with Section 7.5
14of the Physician Assistant Practice Act of 1987, or an
15advanced practice registered nurse who has prescriptive
16authority in accordance with Section 65-40 of the Nurse
17Practice Act may prescribe undesignated oxygen tanks in the
18name of the school district that provides special educational
19facilities for children with disabilities under Section
2014-4.01 of this Code to be maintained for use when necessary.
21Any supply of oxygen tanks shall be maintained in accordance
22with the manufacturer's instructions and with the local fire
23department's rules.
24    (f-3) Whichever entity initiates the process of obtaining
25undesignated epinephrine delivery systems [injectors] and
26providing training to personnel for carrying and administering
		HB3454 Enrolled	- 19 -	LRB104 09749 BDA 19815 b
1undesignated epinephrine delivery systems [injectors] shall pay
2for the costs of the undesignated epinephrine delivery systems
3[injectors].
4    (f-5) Upon any administration of an epinephrine delivery 
5system [injector], a school district, public school, charter
6school, or nonpublic school must immediately activate the EMS
7system and notify the student's parent, guardian, or emergency
8contact, if known.
9    Upon any administration of an opioid antagonist, a school
10district, public school, charter school, or nonpublic school
11must immediately activate the EMS system and notify the
12student's parent, guardian, or emergency contact, if known.
13    (f-10) Within 24 hours of the administration of an
14undesignated epinephrine delivery system [injector], a school
15district, public school, charter school, or nonpublic school
16must notify the physician, physician assistant, or advanced
17practice registered nurse who provided the standing protocol
18and a prescription for the undesignated epinephrine delivery 
19system [injector] of its use.
20    Within 24 hours after the administration of an opioid
21antagonist, a school district, public school, charter school,
22or nonpublic school must notify the health care professional
23who provided the prescription for the opioid antagonist of its
24use.
25    Within 24 hours after the administration of undesignated
26asthma medication, a school district, public school, charter
		HB3454 Enrolled	- 20 -	LRB104 09749 BDA 19815 b
1school, or nonpublic school must notify the student's parent
2or guardian or emergency contact, if known, and the physician,
3physician assistant, or advanced practice registered nurse who
4provided the standing protocol and a prescription for the
5undesignated asthma medication of its use. The district or
6school must follow up with the school nurse, if available, and
7may, with the consent of the child's parent or guardian,
8notify the child's health care provider of record, as
9determined under this Section, of its use.
10    (g) Prior to the administration of an undesignated
11epinephrine delivery system [injector], trained personnel must
12submit to the school's administration proof of completion of a
13training curriculum to recognize and respond to anaphylaxis
14that meets the requirements of subsection (h) of this Section.
15Training must be completed annually. The school district,
16public school, charter school, or nonpublic school must
17maintain records related to the training curriculum and
18trained personnel.
19    Prior to the administration of an opioid antagonist,
20trained personnel must submit to the school's administration
21proof of completion of a training curriculum to recognize and
22respond to an opioid overdose, which curriculum must meet the
23requirements of subsection (h-5) of this Section. The school
24district, public school, charter school, or nonpublic school
25must maintain records relating to the training curriculum and
26the trained personnel.
		HB3454 Enrolled	- 21 -	LRB104 09749 BDA 19815 b
1    Prior to the administration of undesignated asthma
2medication, trained personnel must submit to the school's
3administration proof of completion of a training curriculum to
4recognize and respond to respiratory distress, which must meet
5the requirements of subsection (h-10) of this Section.
6Training must be completed annually, and the school district,
7public school, charter school, or nonpublic school must
8maintain records relating to the training curriculum and the
9trained personnel.
10    (h) A training curriculum to recognize and respond to
11anaphylaxis, including the administration of an undesignated
12epinephrine delivery system [injector], may be conducted online
13or in person.
14    Training shall include, but is not limited to:
15        (1) how to recognize signs and symptoms of an allergic
16    reaction, including anaphylaxis;
17        (2) how to administer an epinephrine delivery system
18    [injector]; and
19        (3) a test demonstrating competency of the knowledge
20    required to recognize anaphylaxis and administer an
21    epinephrine delivery system [injector].
22    Training may also include, but is not limited to:
23        (A) a review of high-risk areas within a school and
24    its related facilities;
25        (B) steps to take to prevent exposure to allergens;
26        (C) emergency follow-up procedures, including the
		HB3454 Enrolled	- 22 -	LRB104 09749 BDA 19815 b
1    importance of calling 9-1-1 or, if 9-1-1 is not available,
2    other local emergency medical services;
3        (D) how to respond to a student with a known allergy,
4    as well as a student with a previously unknown allergy;
5        (E) other criteria as determined in rules adopted
6    pursuant to this Section; and
7        (F) any policy developed by the State Board of
8    Education under Section 2-3.190.
9    In consultation with statewide professional organizations
10representing physicians licensed to practice medicine in all
11of its branches, registered nurses, and school nurses, the
12State Board of Education shall make available resource
13materials consistent with criteria in this subsection (h) for
14educating trained personnel to recognize and respond to
15anaphylaxis. The State Board may take into consideration the
16curriculum on this subject developed by other states, as well
17as any other curricular materials suggested by medical experts
18and other groups that work on life-threatening allergy issues.
19The State Board is not required to create new resource
20materials. The State Board shall make these resource materials
21available on its Internet website.
22    (h-5) A training curriculum to recognize and respond to an
23opioid overdose, including the administration of an opioid
24antagonist, may be conducted online or in person. The training
25must comply with any training requirements under Section 5-23
26of the Substance Use Disorder Act and the corresponding rules.
		HB3454 Enrolled	- 23 -	LRB104 09749 BDA 19815 b
1It must include, but is not limited to:
2        (1) how to recognize symptoms of an opioid overdose;
3        (2) information on drug overdose prevention and
4    recognition;
5        (3) how to perform rescue breathing and resuscitation;
6        (4) how to respond to an emergency involving an opioid
7    overdose;
8        (5) opioid antagonist dosage and administration;
9        (6) the importance of calling 9-1-1 or, if 9-1-1 is
10    not available, other local emergency medical services;
11        (7) care for the overdose victim after administration
12    of the overdose antagonist;
13        (8) a test demonstrating competency of the knowledge
14    required to recognize an opioid overdose and administer a
15    dose of an opioid antagonist; and
16        (9) other criteria as determined in rules adopted
17    pursuant to this Section.
18    (h-10) A training curriculum to recognize and respond to
19respiratory distress, including the administration of
20undesignated asthma medication, may be conducted online or in
21person. The training must include, but is not limited to:
22        (1) how to recognize symptoms of respiratory distress
23    and how to distinguish respiratory distress from
24    anaphylaxis;
25        (2) how to respond to an emergency involving
26    respiratory distress;
		HB3454 Enrolled	- 24 -	LRB104 09749 BDA 19815 b
1        (3) asthma medication dosage and administration;
2        (4) the importance of calling 9-1-1 or, if 9-1-1 is
3    not available, other local emergency medical services;
4        (5) a test demonstrating competency of the knowledge
5    required to recognize respiratory distress and administer
6    asthma medication; and
7        (6) other criteria as determined in rules adopted
8    under this Section.
9    (i) Within 3 days after the administration of an
10undesignated epinephrine delivery system [injector] by a school
11nurse, trained personnel, or a student at a school or
12school-sponsored activity, the school must report to the State
13Board of Education in a form and manner prescribed by the State
14Board the following information:
15        (1) age and type of person receiving epinephrine
16    (student, staff, visitor);
17        (2) any previously known diagnosis of a severe
18    allergy;
19        (3) trigger that precipitated allergic episode;
20        (4) location where symptoms developed;
21        (5) number of doses administered;
22        (6) type of person administering epinephrine (school
23    nurse, trained personnel, student); and
24        (7) any other information required by the State Board.
25    If a school district, public school, charter school, or
26nonpublic school maintains or has an independent contractor
		HB3454 Enrolled	- 25 -	LRB104 09749 BDA 19815 b
1providing transportation to students who maintains a supply of
2undesignated epinephrine delivery systems [injectors], then the
3school district, public school, charter school, or nonpublic
4school must report that information to the State Board of
5Education upon adoption or change of the policy of the school
6district, public school, charter school, nonpublic school, or
7independent contractor, in a manner as prescribed by the State
8Board. The report must include the number of undesignated
9epinephrine delivery systems [injectors] in supply.
10    (i-5) Within 3 days after the administration of an opioid
11antagonist by a school nurse or trained personnel, the school
12must report to the State Board of Education, in a form and
13manner prescribed by the State Board, the following
14information:
15        (1) the age and type of person receiving the opioid
16    antagonist (student, staff, or visitor);
17        (2) the location where symptoms developed;
18        (3) the type of person administering the opioid
19    antagonist (school nurse or trained personnel); and
20        (4) any other information required by the State Board.
21    (i-10) Within 3 days after the administration of
22undesignated asthma medication by a school nurse, trained
23personnel, or a student at a school or school-sponsored
24activity, the school must report to the State Board of
25Education, on a form and in a manner prescribed by the State
26Board of Education, the following information:
		HB3454 Enrolled	- 26 -	LRB104 09749 BDA 19815 b
1        (1) the age and type of person receiving the asthma
2    medication (student, staff, or visitor);
3        (2) any previously known diagnosis of asthma for the
4    person;
5        (3) the trigger that precipitated respiratory
6    distress, if identifiable;
7        (4) the location of where the symptoms developed;
8        (5) the number of doses administered;
9        (6) the type of person administering the asthma
10    medication (school nurse, trained personnel, or student);
11        (7) the outcome of the asthma medication
12    administration; and
13        (8) any other information required by the State Board.
14    (j) By October 1, 2015 and every year thereafter, the
15State Board of Education shall submit a report to the General
16Assembly identifying the frequency and circumstances of
17undesignated epinephrine and undesignated asthma medication
18administration during the preceding academic year. Beginning
19with the 2017 report, the report shall also contain
20information on which school districts, public schools, charter
21schools, and nonpublic schools maintain or have independent
22contractors providing transportation to students who maintain
23a supply of undesignated epinephrine delivery systems
24[injectors]. This report shall be published on the State Board's
25Internet website on the date the report is delivered to the
26General Assembly.
		HB3454 Enrolled	- 27 -	LRB104 09749 BDA 19815 b
1    (j-5) Annually, each school district, public school,
2charter school, or nonpublic school shall request an asthma
3action plan from the parents or guardians of a pupil with
4asthma. If provided, the asthma action plan must be kept on
5file in the office of the school nurse or, in the absence of a
6school nurse, the school administrator. Copies of the asthma
7action plan may be distributed to appropriate school staff who
8interact with the pupil on a regular basis, and, if
9applicable, may be attached to the pupil's federal Section 504
10plan or individualized education program plan.
11    (j-10) To assist schools with emergency response
12procedures for asthma, the State Board of Education, in
13consultation with statewide professional organizations with
14expertise in asthma management and a statewide organization
15representing school administrators, shall develop a model
16asthma episode emergency response protocol before September 1,
172016. Each school district, charter school, and nonpublic
18school shall adopt an asthma episode emergency response
19protocol before January 1, 2017 that includes all of the
20components of the State Board's model protocol.
21    (j-15) (Blank).
22    (j-20) On or before October 1, 2016 and every year
23thereafter, the State Board of Education shall submit a report
24to the General Assembly and the Department of Public Health
25identifying the frequency and circumstances of opioid
26antagonist administration during the preceding academic year.
		HB3454 Enrolled	- 28 -	LRB104 09749 BDA 19815 b
1This report shall be published on the State Board's Internet
2website on the date the report is delivered to the General
3Assembly.
4    (k) The State Board of Education may adopt rules necessary
5to implement this Section.
6    (l) Nothing in this Section shall limit the amount of
7epinephrine delivery systems [injectors] that any type of school
8or student may carry or maintain a supply of.
9(Source: P.A. 102-413, eff. 8-20-21; 102-813, eff. 5-13-22;
10103-175, eff. 6-30-23; 103-196, eff. 1-1-24; 103-348, eff.
111-1-24; 103-542, eff. 7-1-24 (see Section 905 of P.A. 103-563
12for effective date of P.A. 103-542); 103-605, eff. 7-1-24.)
13    Section 20. The Illinois Insurance Code is amended by
14changing Section 356z.33 as follows:
15    (215 ILCS 5/356z.33)
16    Sec. 356z.33. Coverage for epinephrine delivery systems
17[epinephrine injectors].
18    (a) A group or individual policy of accident and health
19insurance or a managed care plan that is amended, delivered,
20issued, or renewed on or after January 1, 2020 (the effective
21date of Public Act 101-281) shall provide coverage for
22medically necessary epinephrine delivery systems [epinephrine ]
23[injectors] for persons 18 years of age or under. As used in this
24Section, "epinephrine delivery system" ["epinephrine injector"]
		HB3454 Enrolled	- 29 -	LRB104 09749 BDA 19815 b
1has the meaning given to that term in Section 5 of the
2Epinephrine Delivery System [Epinephrine Injector] Act.
3    (b) An insurer that provides coverage for medically
4necessary epinephrine delivery systems [epinephrine injectors]
5shall limit the total amount that an insured is required to pay
6for a twin-pack of medically necessary epinephrine delivery 
7systems [epinephrine injectors] at an amount not to exceed $60,
8regardless of the type of epinephrine delivery system
9[epinephrine injector]; except that this provision does not
10apply to the extent such coverage would disqualify a
11high-deductible health plan from eligibility for a health
12savings account pursuant to Section 223 of the Internal
13Revenue Code (26 U.S.C. 223).
14    (c) Nothing in this Section prevents an insurer from
15reducing an insured's cost sharing by an amount greater than
16the amount specified in subsection (b).
17    (d) The Department may adopt rules as necessary to
18implement and administer this Section.
19(Source: P.A. 102-558, eff. 8-20-21; 103-454, eff. 1-1-25;
20103-718, eff. 7-19-24.)
21    Section 25. The Medical Practice Act of 1987 is amended by
22changing Section 65 as follows:
23    (225 ILCS 60/65)
24    (Section scheduled to be repealed on January 1, 2027)
		HB3454 Enrolled	- 30 -	LRB104 09749 BDA 19815 b
1    Sec. 65. Annie LeGere Law; epinephrine delivery system
2[epinephrine auto-injector]. A licensee under this Act may not
3be subject to discipline for providing a standing order or
4prescription for an epinephrine delivery system [epinephrine ]
5[auto-injector] in accordance with Section 40 of the Illinois
6State Police Act or Section 10.19 of the Illinois Police
7Training Act.
8(Source: P.A. 102-538, eff. 8-20-21.)
9    Section 30. The Epinephrine Injector Act is amended by
10changing Sections 1, 5, 10, 15, and 20 as follows:
11    (410 ILCS 27/1)
12    Sec. 1. Short title. This Act may be cited as the
13Epinephrine Delivery System [Epinephrine Injector] Act.
14(Source: P.A. 99-711, eff. 1-1-17; 100-799, eff. 1-1-19.)
15    (410 ILCS 27/5)
16    Sec. 5. Definitions. As used in this Act:
17    "Administer" means to directly apply an epinephrine
18delivery system to the body of an individual.
19    "Authorized entity" means any entity or organization,
20other than a school covered under Section 22-30 of the School
21Code, in connection with or at which allergens capable of
22causing anaphylaxis may be present, including, but not limited
23to, independent contractors who provide student transportation
		HB3454 Enrolled	- 31 -	LRB104 09749 BDA 19815 b
1to schools, recreation camps, colleges and universities, day
2care facilities, youth sports leagues, amusement parks,
3restaurants, sports arenas, and places of employment. The
4Department shall, by rule, determine what constitutes a day
5care facility under this definition.
6    "Authorized individual" means an individual who has
7successfully completed the training program under Section 10
8of this Act.
9    "Department" means the Department of Public Health.
10    "Epinephrine delivery system" means any form of
11epinephrine that is approved by the United States Food and
12Drug Administration, including any device that contains a dose
13of epinephrine, and that is used to administer epinephrine
14into the human body to prevent or treat a life-threatening
15allergic reaction.
16    "Health care practitioner" means a physician licensed to
17practice medicine in all its branches under the Medical
18Practice Act of 1987, a physician assistant under the
19Physician Assistant Practice Act of 1987 with prescriptive
20authority, or an advanced practice registered nurse with
21prescribing authority under Article 65 of the Nurse Practice
22Act.
23    "Pharmacist" has the meaning given to that term under
24subsection (k-5) of Section 3 of the Pharmacy Practice Act.
25    "Undesignated epinephrine delivery system [injector]" means
26an epinephrine delivery system [injector] prescribed in the name
		HB3454 Enrolled	- 32 -	LRB104 09749 BDA 19815 b
1of an authorized entity.
2(Source: P.A. 104-229, eff. 1-1-26.)
3    (410 ILCS 27/10)
4    Sec. 10. Prescription to authorized entity; use; training.
5    (a) A health care practitioner may prescribe epinephrine
6delivery systems [injectors] in the name of an authorized entity
7or authorized individual for use in accordance with this Act,
8and pharmacists and health care practitioners may dispense
9epinephrine delivery systems pursuant to a prescription issued
10in the name of an authorized entity or authorized individual.
11Such prescriptions shall be valid for a period of 2 years.
12    (a-1) A health care provider with prescribing authority
13who is employed by or under contract with the Department may
14issue a statewide standing order for the dispensing of
15epinephrine delivery systems for use under subsection (c) by
16authorized individuals or by employees or agents of authorized
17entities who have completed the training required by
18subsection (d).
19    (b) An authorized entity or authorized individual may
20acquire and stock a supply of undesignated epinephrine
21delivery systems pursuant to a prescription issued under
22subsection (a) of this Section. Such undesignated epinephrine
23delivery systems shall be stored in a location readily
24accessible in an emergency and in accordance with the
25instructions for use of the epinephrine delivery systems. The
		HB3454 Enrolled	- 33 -	LRB104 09749 BDA 19815 b
1Department may establish any additional requirements an
2authorized entity or authorized individual must follow under
3this Act.
4    (c) An employee or agent of an authorized entity who is an
5authorized individual or any other individual who is an
6authorized individual may:
7        (1) anywhere allergens capable of causing anaphylaxis
8    may be present provide an epinephrine delivery system to
9    any individual whom the employee, agent, or other
10    individual believes in good faith is experiencing
11    anaphylaxis, or to the parent, guardian, or caregiver of
12    such individual, for immediate administration, regardless
13    of whether the individual has a prescription for an
14    epinephrine delivery system or has previously been
15    diagnosed with an allergy; or
16        (2) anywhere allergens capable of causing anaphylaxis
17    may be present administer an epinephrine delivery system
18    to any individual whom the employee, agent, or other
19    individual believes in good faith is experiencing
20    anaphylaxis, regardless of whether the individual has a
21    prescription for an epinephrine delivery system or has
22    previously been diagnosed with an allergy.
23    (d) An employee, agent, or other individual authorized
24must complete an anaphylaxis training program before he or she
25is able to provide or administer an epinephrine delivery
26system under this Section. Such training shall be valid for a
		HB3454 Enrolled	- 34 -	LRB104 09749 BDA 19815 b
1period of 2 years and shall be conducted by a nationally
2recognized organization experienced in training laypersons in
3emergency health treatment. The Department shall include links
4to training providers' websites on its website.
5    Training shall include, but is not limited to:
6        (1) how to recognize signs and symptoms of an allergic
7    reaction, including anaphylaxis;
8        (2) how to administer an epinephrine delivery system;
9    and
10        (3) a test demonstrating competency of the knowledge
11    required to recognize anaphylaxis and administer an
12    epinephrine delivery system.
13    Training may also include, but is not limited to:
14        (A) a review of high-risk areas on the authorized
15    entity's property and its related facilities;
16        (B) steps to take to prevent exposure to allergens;
17        (C) emergency follow-up procedures; and
18        (D) other criteria as determined in rules adopted
19    pursuant to this Act.
20    Training may be conducted either online or in person. The
21entity or individual conducting the training shall issue a
22certificate to each person who successfully completes the
23anaphylaxis training program. The Department shall approve
24training programs and list permitted training programs on the
25Department's Internet website.
26(Source: P.A. 104-229, eff. 1-1-26.)
		HB3454 Enrolled	- 35 -	LRB104 09749 BDA 19815 b
1    (410 ILCS 27/15)
2    Sec. 15. Costs. Whichever entity initiates the process of
3obtaining undesignated epinephrine delivery systems and
4providing training to personnel for carrying and administering
5undesignated epinephrine delivery systems shall pay for the
6costs of the undesignated epinephrine delivery systems.
7(Source: P.A. 104-229, eff. 1-1-26.)
8    (410 ILCS 27/20)
9    Sec. 20. Limitations. The use of an undesignated
10epinephrine delivery system in accordance with the
11requirements of this Act does not constitute the practice of
12medicine or any other profession that requires medical
13licensure.
14    Nothing in this Act shall limit the amount of epinephrine
15delivery systems that an authorized entity or individual may
16carry or maintain a supply of.
17(Source: P.A. 104-229, eff. 1-1-26.)
18    Section 35. The Emergency Asthma Inhalers and Allergy
19Treatment for Children Act is amended by changing Section 10
20as follows:
21    (410 ILCS 607/10)
22    Sec. 10. Possession, self-administration, and use of
		HB3454 Enrolled	- 36 -	LRB104 09749 BDA 19815 b
1epinephrine delivery systems [epinephrine auto-injectors] or
2inhalers at recreation camps and after-school care programs.
3    (a) A recreation camp or an after-school care program
4shall permit a child with severe, potentially life-threatening
5allergies to possess, self-administer, and use an epinephrine 
6delivery system [epinephrine auto-injector] or inhaler, if the
7following conditions are satisfied:
8        (1) The child has the written approval of his or her
9    parent or guardian.
10        (2) The recreational camp or after-school care program
11    administrator or, if a nurse is assigned to the camp or
12    program, the nurse shall receive copies of the written
13    approvals required under paragraph (1) of subsection (a)
14    of this Section.
15        (3) The child's parent or guardian shall submit
16    written verification confirming that the child has the
17    knowledge and skills to safely possess, self-administer,
18    and use an epinephrine delivery system [epinephrine ]
19    [auto-injector] or inhaler in a camp or an after-school care
20    program setting.
21    (b) The child's parent or guardian shall provide the camp
22or program with the following information:
23        (1) the child's name;
24        (2) the name, route, and dosage of medication;
25        (3) the frequency and time of medication
26    administration or assistance;
		HB3454 Enrolled	- 37 -	LRB104 09749 BDA 19815 b
1        (4) the date of the order;
2        (5) a diagnosis and any other medical conditions
3    requiring medications, if not a violation of
4    confidentiality or if not contrary to the request of the
5    parent or guardian to keep confidential;
6        (6) specific recommendations for administration;
7        (7) any special side effects, contraindications, and
8    adverse reactions to be observed;
9        (8) the name of each required medication; and
10        (9) any severe adverse reactions that may occur to
11    another child, for whom the epinephrine delivery system
12    [epinephrine auto-injector] or inhaler is not prescribed,
13    should the other child receive a dose of the medication.
14    (c) If the conditions of this Act are satisfied, the child
15may possess, self-administer, and use an epinephrine delivery 
16system [epinephrine auto-injector] or inhaler at the camp or
17after-school care program or at any camp-sponsored or
18program-sponsored activity, event, or program.
19    (d) The recreational camp or after-school care program
20must inform the parents or guardians of the child, in writing,
21that the recreational camp or after-school care program and
22its employees and agents are to incur no liability, as
23applicable, except for willful and wanton conduct, as a result
24of any injury arising from the self-administration of
25medication to the child. The parents or guardians of the child
26must sign a statement acknowledging that the recreational camp
		HB3454 Enrolled	- 38 -	LRB104 09749 BDA 19815 b
1or after-school care program is to incur no liability, except
2for willful and wanton conduct, as a result of any injury
3arising from the self-administration of medication by the
4child and that the parents or guardians must indemnify and
5hold harmless the recreational camp or after-school care
6program and its employees and agents, as applicable, against
7any claims, except a claim based on willful and wanton
8conduct, arising out of the self-administration of medication
9by the child.
10    (e) After-school care program personnel who have completed
11an anaphylaxis training program as identified under the
12Epinephrine Delivery System [Epinephrine Injector] Act may
13administer an undesignated epinephrine injection to any child
14if the after-school care program personnel believe in good
15faith that the child is having an anaphylactic reaction while
16in the after-school care program. After-school care program
17personnel may carry undesignated epinephrine delivery systems
18[epinephrine injectors] on their person while in the
19after-school care program.
20    (f) After-school care program personnel may administer
21undesignated asthma medication to any child if the
22after-school care program personnel believe in good faith that
23the child is experiencing respiratory distress while in the
24after-school care program. After-school care program personnel
25may carry undesignated asthma medication on their person while
26in the after-school care program.
		HB3454 Enrolled	- 39 -	LRB104 09749 BDA 19815 b
1    (g) If after-school care program personnel are to
2administer an undesignated epinephrine injection or an
3undesignated asthma medication to a child, the after-school
4care program personnel must inform the parents or guardians of
5the child, in writing, that the after-school care program and
6its employees and agents, acting in accordance with standard
7protocols and the prescription for the injection or
8medication, shall incur no liability, except for willful and
9wanton conduct, as a result of any injury arising from the
10administration of the injection or medication, notwithstanding
11whether authorization was given by the child's parents or
12guardians or by the child's physician, physician assistant, or
13advanced practice registered nurse. A parent or guardian of
14the child must sign a statement acknowledging that the
15after-school care program and its employees and agents are to
16incur no liability, except for willful and wanton conduct, as
17a result of any injury arising from the administration of the
18medication or injection, regardless of whether authorization
19was given by a parent or guardian of the child or by the
20child's physician, physician assistant, or advanced practice
21registered nurse, and that the parent or guardian must also
22indemnify and hold harmless the after-school care program and
23its employees and agents against any claims, except a claim
24based on willful and wanton conduct, arising out of the
25administration of the medication or injection, regardless of
26whether authorization was given by the child's parent or
		HB3454 Enrolled	- 40 -	LRB104 09749 BDA 19815 b
1guardian or by the child's physician, physician assistant, or
2advanced practice registered nurse.
3    (h) If after-school care program personnel administer an
4undesignated epinephrine injection to a person and the
5after-school care program personnel believe in good faith the
6person is having an anaphylactic reaction or administer
7undesignated asthma medication to a person and believe in good
8faith the person is experiencing respiratory distress, then
9the after-school care program and its employees and agents,
10acting in accordance with standard protocols and the
11prescription for the injection or medication, shall not incur
12any liability or be subject to professional discipline, except
13for willful and wanton conduct, as a result of any injury
14arising from the use of the injection or medication,
15notwithstanding whether notice was given to or authorization
16was given by the child's parent or guardian or by the child's
17physician, physician assistant, or advanced practice
18registered nurse and notwithstanding the absence of the
19parent's or guardian's signed statement acknowledging release
20from liability.
21    (i) The changes made to this Section by this amendatory
22Act of the 103rd General Assembly apply to actions filed on or
23after the effective date of this amendatory Act of the 103rd
24General Assembly.
25(Source: P.A. 103-438, eff. 8-4-23.)
		HB3454 Enrolled	- 41 -	LRB104 09749 BDA 19815 b
1    Section 40. The Illinois Food, Drug and Cosmetic Act is
2amended by changing Section 3.21 as follows:
3    (410 ILCS 620/3.21)  (from Ch. 56 1/2, par. 503.21)
4    Sec. 3.21. Except as authorized by this Act, the Illinois
5Controlled Substances Act, the Pharmacy Practice Act, the
6Dental Practice Act, the Medical Practice Act of 1987, the
7Veterinary Medicine and Surgery Practice Act of 2004, the
8Podiatric Medical Practice Act of 1987, Section 22-30 of the
9School Code, Section 40 of the Illinois State Police Act,
10Section 10.19 of the Illinois Police Training Act, or the
11Epinephrine Delivery System [Epinephrine Injector] Act, to sell
12or dispense a prescription drug without a prescription.
13(Source: P.A. 102-538, eff. 8-20-21.)